Active and Passive Anticytokine Immune Therapies: Current Status and Development

Advances in Immunology

Volumn 115, Issue , 2012, Pages 187-227

  Le Buanec, Hélène ^a,b,c   Bensussan, Armand ^a,b,c   Bagot, Martine ^a,b,c   Gallo, Robert C ^d   Zagury, Daniel ^e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITY OF MARYLAND   (United States)

^e Neovacs SA   (France)

Author keywords

AC immune therapies; Cytokines; Novel biotherapies

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTIFERON; BELIMUMAB; BEVACIZUMAB; CANAKINUMAB; CERTOLIZUMAB PEGOL; CYTOKINE ANTIBODY; D2E7; DENOSUMAB; GAMMA INTERFERON; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23P19; INTERLEUKIN 5; INTERLEUKIN 6; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 5; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; RANIBIZUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VASCULOTROPIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTIVE IMMUNIZATION; ALLERGY; ANKYLOSING SPONDYLITIS; ANTIGEN PRESENTING CELL; ARTICLE; ASTHMA; AUTOCRINE EFFECT; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; B LYMPHOCYTE; BINDING AFFINITY; BONE DISEASE; BREAST CANCER; CACHEXIA; CANCER CELL; CHRONIC DISEASE; CINCA SYNDROME; COLORECTAL CANCER; CROHN DISEASE; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; ENTERITIS; GLIOBLASTOMA; GOUT; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LEIOMYOSARCOMA; LEISHMANIASIS; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARACRINE SIGNALING; PASSIVE IMMUNIZATION; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; PSORIATIC ARTHRITIS; RECEPTOR BINDING; RETINA MACULA DEGENERATION; RHABDOMYOSARCOMA; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT OUTCOME; ULCERATIVE COLITIS; VIRUS INFECTION;

EID: 84861131253     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394299-9.00007-2     Document Type: Chapter

References (181)

1. Andreakos E.T., Foxwell B.M., Brennan F.M., Maini R.N., Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: Present and future. Cytokine Growth Factor Rev. 2002, 13:299-313.
2. Angelo L.S., Talpaz M., Kurzrock R. Autocrine interleukin-6 production in renal cell carcinoma: Evidence for the involvement of p53. Cancer Res. 2002, 62:932-940.
3. Badou A., Bennasser Y., Moreau M., Leclerc C., Benkirane M., Bahraoui E. Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: Implication of protein kinase C-dependent pathway. J. Virol. 2000, 74:10551-10562.
4. Baecklund E., Iliadou A., Askling J., Ekbom A., Backlin C., Granath F., Catrina A.I., Rosenquist R., Feltelius N., Sundström C., Klareskog L. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006, 54:692-701.
5. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 2003, 348:601-608.
6. Balkwill F.R., Mantovani A. Cancer-related inflammation: Common themes and therapeutic opportunities. Semin. Cancer Biol. 2012, 22:33-40.
7. Bequet-Romero M., López-Ocejo O. Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochem. Biophys. Res. Commun. 2000, 277:55-61.
8. Bertin-Maghit S.M., Capini C.J., Bessis N., Chomilier J., Muller S., Abbas A., Autin L., Spadoni J.L., Rappaport J., Therwath A., Boissier M.C., Zagury J.F. Improvement of collagen-induced arthritis by active immunisation against murine IL-1 beta peptides designed by molecular modelling. Vaccine 2005, 23:4228-4235.
9. Bigot K., Provost A., Grouard-Vogel G., Zeghidi H., Bernier E., Adam-BuczKwski E., Zagury D., Abitbol M. Encouraging results of a VEGF kinoid against experimental choroidal neovascularization. EVER Congress 2009, September 30-October 3, Portoroz, Slovenia.
10. Bizzini B., Achour A. " Kinoids": The basis for anticytokine immunisation and their use in HIV infection. Cell. Mol. Biol. (Noisy-le-Grand) 1995, 41:351-356.
11. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35:630-640.
12. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
13. Bonino F., Baldi M., Negro F., Oliveri F., Colombatto P., Bellati G., Brunetto M.R. Clinical relevance of anti-interferon antibodies in the serum of chronic hepatitis C patients treated with interferon-alpha. J. Interferon Cytokine Res. 1997, 17(Suppl. 1):S35-S38.
14. Boon T., Coulie P.G., Van den Eynde B.J., van der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol. 2006, 24:175-208. Review.
15. Botti C., Seregni E., Ferrari L., Martinetti A., Bombardieri E. Immunosuppressive factors: Role in cancer development and progression. Int. J. Biol. Markers 1998, 13:51-69.
16. Boulianne G.L., Hozumi N., Shulman M.J. Production of functional chimaeric mouse/human antibody. Nature 1984, 312:643-646.
17. Butler D.M., Maini R.N., Feldmann M., Brennan F.M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur. Cytokine Netw. 1995, 6:225-230.
18. Capini C.J., Bertin-Maghit S.M., Bessis N., Haumont P.M., Bernier E.M., Muel E.G., Laborie M.A., Autin L., Paturance S., Chomilier J., Boissier M.C., Briand J.P., et al. Active immunisation against murine TNFalpha peptides in mice: Generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. Vaccine 2004, 22:3144-3153.
19. Carelli C., Halbreich A., Bernard J., Bizzini B., Achour A., Zagury J.F., Lebon P., Polliotti B., Folghera S., Laaroubi K., et al. Immunogenicity of combined anti-HIV and anti-suppressive vaccine preparations. Biomed. Pharmacother. 1992, 46:149-153.
20. Caruso A., Turano A. Natural antibodies to interferon-gamma. Biotherapy 1997, 10:29-37.
21. Chackerian B., Lowy D.R., Schiller J.T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 2001, 108:415-423.
22. Chakravarty E.F., Genovese M.C. Associations between rheumatoid arthritis and malignancy. Rheum. Dis. Clin. North Am. 2004, 30:271-284.
23. Chen C.H., Wu T.C. Experimental vaccine strategies for cancer immunotherapy. J. Biomed. Sci. 1998, 5:231-252. Review.
24. Chen Y., Langrish C.L., McKenzie B., Joyce-Shaikh B., Stumhofer J.S., McClanahan T.K., Blumenschein W., Churakovsa T., Low J., Presta L., Hunter C.A., Kastelein R.A., et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 2006, 116:1317-1326.
25. Chensue S.W., Terebuh P.D., Remick D.G., Scales W.E., Kunkel S.L. In vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer cell expression, and glucocorticoid effects. Am. J. Pathol. 1991, 138:395-402.
26. Chizzonite R., Truitt T., Desai B.B., Nunes P., Podlaski F.J., Stern A.S., Gately M.K. IL-12 receptor (1992). I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J. Immunol. 1992, 148:3117-3124.
27. Constantinescu C.S., Hondowicz B.D., Elloso M.M., Wysocka M., Trinchieri G., Scott P. The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis. Eur. J. Immunol. 1998, 28:2227-2233.
28. Dalum I., Butler D.M., Jensen M.R., Hindersson P., Steinaa L., Waterston A.M., Grell S.N., Feldmann M., Elsner H.I., Mouritsen S. Therapeutic antibodies elicited by immunisation against TNF-alpha. Nat. Biotechnol. 1999, 17:666-669.
29. Debray-Sachs M., Carnaud C., Boitard C., Cohen H., Gresser I., Bedossa P., Bach J.F. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J. Autoimmun. 1991, 4:237-248.
30. Delavallée L., Assier E., Denys A., Falgarone G., Zagury J.F., Muller S., Bessis N., Boissier M.C. Vaccination with cytokines in autoimmune diseases. Ann. Med. 2008, 40:343-351.
31. Dinarello C.A. Anti-inflammatory agents: Present and future. Cell 2010, 140:935-950.
32. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F.M., Walker J., Bijl H., Ghrayeb J., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993, 36:1681-1690.
33. Elson C.O., Cong Y., Weaver C.T., Schoeb T.R., McClanahan T.K., Fick R.B., Kastelein R.A. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007, 132:2359-2370.
34. ® (etanercept), prescribing information 2007, Immunex Corp, CA, USA.
35. Exley A.R., Cohen J., Buurman W., Owen R., Hanson G., Lumley J., Aulakh J.M., Bodmer M., Riddell A., Stephens S., et al. Monoclonal antibody to TNF in severe septic shock. Lancet 1990, 335:1275-1277.
36. Fauci A.S., Gallo R.C., Koenig S., Salk J., Purcell R.H. NIH conference. Development and evaluation of a vaccine for human immunodeficiency virus (HIV) infection. Ann. Intern. Med. 1989, 110:373-385.
37. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996, 14:397-440.
38. Felson D.T., Anderson J.J., Boers M., Bombardier C., Furst D., Goldsmith C., Katz L.M., Lightfoot R., Paulus H., Strand V., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995, 38:727-735.
39. Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: From basic science to therapy. Nat. Med. 2010, 16:1107-1111.
40. Folkman J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
41. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 1992, 3:65-71.
42. Folkman J. Angiogenesis: An organizing principle for drug discovery?. Nat. Rev. Drug Discov. 2007, 6:273-286.
43. Foote J., Eisen H.N. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA 1995, 92:1254-1256.
44. Francis M.L., Meltzer M.S., Gendelman H.E. Interferons in the persistence, pathogenesis, and treatment of HIV infection. AIDS Res. Hum. Retroviruses 1992, 8:199-207. Review.
45. Friguet B., Chaffotte A.F., Djavadi-Ohaniance L., Goldberg M.E. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods 1985, 77:305-319.
46. Galle P., Jensen L., Andersson C., Cuzzocrea S., Di Paola R., Nicoletti F., Svenson M., Bendtzen K., Thomsen A.R., Hansen M.B. Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation. Int. Immunopharmacol. 2007, 7:1704-1713.
47. Gallo R.C. Tat as one key to HIV-induced immune pathogenesis and Tat toxoid as an important component of a vaccine. Proc. Natl. Acad. Sci. USA 1999, 96:8324-8326.
48. Ganapathy V., Ge R., Grazioli A., Xie W., Banach-Petrosky W., Kang Y., Lonning S., McPherson J., Yingling J.M., Biswas S., Mundy G.R., Reiss M. Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol. Cancer 2010, 9:122.
49. Gerber H.P., Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J. Mol. Med. (Berl.) 2003, 81:20-31.
50. Gibellini D., Zauli G., Re M.C., Milani D., Furlini G., Caramelli E., Capitani S., La Placa M. Recombinant human immunodeficiency virus type-1 (HIV-1) Tat protein sequentially up-regulates IL-6 and TGF-beta 1 mRNA expression and protein synthesis in peripheral blood monocytes. Br. J. Haematol. 1994, 88:261-267.
51. Green L.L., Hardy M.C., Maynard-Currie C.E., Tsuda H., Louie D.M., Mendez M.J., Abderrahim H., Noguchi M., Smith D.H., Zeng Y., et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. 1994, 7:13-21.
52. Grell M., Wajant H., Zimmermann G., Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl. Acad. Sci. USA 1998, 95:570-575.
53. Gringeri A., Santagostino E., Mannucci P.M., Tradati F., Cultraro D., Buzzi A., Criscuolo M., David A., Guillemot L., Barré-Sinoussi F., et al. A randomized, placebo-controlled, blind anti-AIDS clinical trial: Safety and immunogenicity of a specific anti-IFN alpha immunisation. J. Acquir. Immune Defic. Syndr. 1994, 7:978-988.
54. Gringeri A., Santagostino E., Cusini M., Muça-Perja M., Marinoni A., Mannucci P.M., Burny A., Criscuolo M., Lu W., Andrieru J.M., Mbika J.P., Lachgar A., et al. Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunisation: A 30-month follow-up report. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996, 13:55-67.
55. Gringeri A., Musicco M., Hermans P., Bentwich Z., Cusini M., Bergamasco A., Santagostino E., Burny A., Bizzini B., Zagury D. Active anti-interferon-alpha immunisation: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS study). J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1999, 20:358-370.
56. Han D.C., Ziyadeh F.N. Favorable treatment outcome with neutralizing anti transforming growth factor beta antibodies in experimental diabetic kidney disease. Perit. Dial. Int. 1999, 19(Suppl. 2):S234-S237.
57. Harding F.A., Stickler M.M., Razo J., DuBridge R.B. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010, 2:256-265.
58. Hofstetter H.H., Ibrahim S.M., Koczan D., Kruse N., Weishaupt A., Toyka K.V., Gold R. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell. Immunol. 2005, 237:123-130.
59. Hondowicz B.D., Park A.Y., Elloso M.M., Scott P. Maintenance of IL-12-responsive CD4+ T cells during a Th2 response in Leishmania major-infected mice. Eur. J. Immunol. 2000, 30:2007-2014.
60. Houssiau F.A., Rashkov R., Hachulla E., Lazaro E., Jorgensen C., Spertini F., Mariette X., Grouard-Vogel G., Fanget B., Dhellin O., Lauwerys B., Vandepapeliere P. Active Immunization Against IFNa with IFN-Kinoid in SLE Patients Is Safe, Immunogenic and Induces Down-Regulation of IFN Mediated Genes. Arthritis & Rheumatism 63 (S10) Abstract 2470 - The American College of Rheumatology/Association of Rheumatology Health Professionals. Annual Scientific Meeting 2011, Chicago, Illinois.
61. Hsieh C.L., Chen D.S., Hwang L.H. Tumor-induced immunosuppression: A barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum. Gene Ther. 2000, 11:681-692.
62. Hue S., Ahern P., Buonocore S., Kullberg M.C., Cua D.J., McKenzie B., Powrie F., Maloy K.J. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 2006, 203:2473-2493.
63. Ishida H., Muchamuel T., Sakaguchi S., Andrade S., Menon S., Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 1994, 179:305-310.
64. Immunotherapy for Infectious Diseases 2002, Human Press Inc., Totowa, NJ, 331pp. (Eng). J.M. Jacobson (Ed.).
65. Jakowlew S.B. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006, 25:435-457.
66. Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321:522-525.
67. Jurlander J., Lai C.F., Tan J., Chou C.C., Geisler C.H., Schriber J., Blumenson L.E., Narula S.K., Baumann H., Caligiuri M.A. Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood 1997, 89:4146-4152.
68. Kaiser P.K., Symons R.C., Shah S.M., Quinlan E.J., Tabandeh H., Do D.V., Reisen G., Lockridge J.A., Short B., Guerciolini R., Nguyen Q.D., Sirna-027 Study Investigators RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am. J. Ophthalmol. 2010, 150:33-39.
69. Kanegane H., Wakiguchi H., Kanegane C., Kurashige T., Tosato G. Viral interleukin-10 in chronic active Epstein-Barr virus infection. J. Infect. Dis. 1997, 176:254-257.
70. Karcher J., Reisser C., Daniel V., Herold-Mende C. Cytokine expression of transforming growth factor-beta2 and interleukin-10 in squamous cell carcinomas of the head and neck. Comparison of tissue expression and serum levels. HNO 1999, 47:879-884.
71. Kasper C. Erythropoietin. The cytokine handbook 2003, 149-166. Elsevier, London, vol I. 4th edn. A.W. Thomson, M.T. Lotze (Eds.).
72. Kaymakcalan Z., Sakorafas P., Bose S., Scesney S., Xiong L., Hanzatian D.K., Salfeld J., Sasso E.H. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin. Immunol. 2009, 131:308-316.
73. Keir M.E., Stoddart C.A., Linquist-Stepps V., Moreno M.E., McCune J.M. IFN-alpha secretion by type 2 predendritic cells up-regulates MHC class I in the HIV-1-infected thymus. J. Immunol. 2002, 168:325-331.
74. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4:423-436.
75. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
76. Klein B., Wijdenes J., Zhang X.G., Jourdan M., Boiron J.M., Brochier J., Liautard J., Merlin M., Clement C., Morel-Fournier B., et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991, 78:1198-1204.
77. Kobayashi M., Tanaka J., Imamura M., Maeda S., Iwasaki H., Tanaka M., Tsudu Y., Sakurada K., Miyazaki T. Up-regulation of IL-6-receptors by IL-3 on a plasma cell leukaemia cell line which proliferates dependently on both IL-3 and IL-6. Br. J. Haematol. 1993, 83:535-538.
78. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
79. Kojouharoff G., Hans W., Obermeier F., Männel D.N., Andus T., Schölmerich J., Gross V., Falk W. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin. Exp. Immunol. 1997, 107:353-358.
80. Kopf M., Bachmann M.F., Marsland B.J. Averting inflammation by targeting the cytokine environment. Nat. Rev. Drug Discov. 2010, 9:703-718.
81. Kostenuik P.J., Smith S.Y., Jolette J., Schroeder J., Pyrah I., Ominsky M.S. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 2011, 49:151-161.
82. Kumar R.K., Herbert C., Webb D.C., Li L., Foster P.S. Effects of anticytokine therapy in a mouse model of chronic asthma. Am. J. Respir. Crit. Care Med. 2004, 170:1043-1048.
83. Lanzavecchia A., Corti D., Sallusto F. Human monoclonal antibodies by immortalization of memory B cells. Curr. Opin. Biotechnol. 2007, 18:523-528.
84. Le Buanec H., Lachgar A., D'Anna R., Zagury J.F., Bizzini B., Bernard J., Ittelé D., Hallez S., Giannouli C., Burny A., Zagury D. Induction of cellular immunosuppression by the human papillomavirus type 16 E7 oncogenic protein. Biomed. Pharmacother. 1999, 53:323-328.
85. Le Buanec H., D'Anna R., Lachgar A., Zagury J.F., Bernard J., Ittelé D., d'Alessio P., Hallez S., Giannouli C., Burny A., Bizzini B., Gallo R.C., et al. HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes. Biomed. Pharmacother. 1999, 53:424-431.
86. Le Buanec H., Delavallée L., Bessis N., Paturance S., Bizzini B., Gallo R., Zagury D., Boissier M.C. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc. Natl. Acad. Sci. USA 2006, 103:19442-19447.
87. Le Buanec H., Paturance S., Couillin I., Schnyder-Candrian S., Larcier P., Ryffel B., Bizzini B., Bensussan A., Burny A., Gallo R., Zagury D., Peltre G. Control of allergic reactions in mice by an active anti-murine IL-4 immunisation. Vaccine 2007, 25:7206-7216.
88. Le Buanec H., Gougeon M.L., Mathian A., Lebon P., Dupont J.M., Peltre G., Hemon P., Schmid M., Bizzini B., Künding T., Burny A., Bensussan A., et al. IFN-α and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. Proc. Natl. Acad. Sci. USA 2011, 108:18995-19000.
89. Leonard J.P., Waldburger K.E., Goldman S.J. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 1995, 181:381-386.
90. Li X., Loberg R., Liao J., Ying C., Snyder L.A., Pienta K.J., McCauley L.K. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res. 2009, 69:1685-1692.
91. Lin J., Ziring D., Desai S., Kim S., Wong M., Korin Y., Braun J., Reed E., Gjertson D., Singh R.R. TNFalpha blockade in human diseases: An overview of efficacy and safety. Clin. Immunol. 2008, 126:13-30.
92. Loberg R.D., Ying C., Craig M., Day L.L., Sargent E., Neeley C., Wojno K., Snyder L.A., Yan L., Pienta K.J. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007, 67:9417-9424.
93. Lonberg N., Huszar D. Human antibodies from transgenic mice. Int. Rev. Immunol. 1995, 13(1):65-93.
94. Lu X., Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J. Biol. Chem. 2009, 284:29087-29096.
95. Lubberts E., Koenders M.I., Oppers-Walgreen B., Van den Bersselaar L., Coenen-de Roo C.J.J., Joosten L.A.B., van den Berg W.B. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen- induced arthritis reduces joint inflammation, cartilage destructionand bone erosion. Arthritis Rheum. 2004, 50:650-659.
96. Ma Y., Hayglass K.T., Becker A.B. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am. J. Resp. Crit. Care Med. 2007, 176:439-445.
97. Maini R.N., Elliott M., Brennan F.M., Williams R.O., Feldmann M. Targeting TNF alpha for the therapy of rheumatoid arthritis. Clin. Exp. Rheumatol. 1994, 12(Suppl. 11):S63-S66.
98. Martiny-Baron G., Marmé D. VEGF-mediated tumour angiogenesis: A new target for cancer therapy. Curr. Opin. Biotechnol. 1995, 6:675-680.
99. Mathian A., Amoura Z., Adam E., Colaone F., Hoekman M.F., Dhellin O., Vandepapelière P., Haroche J., Piette J.C., Lebon P., Grouard-Vogel G. Active immunisation of human interferon α transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2011, 70:1138-1143.
100. Matthys P., Vermeire K., Mitera T., Heremans H., Huang S., Billiau A. Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-gamma receptor-deficient mice. Eur. J. Immunol. 1998, 28:2143-2151.
101. Mauser P.S., Pitman A., Witt A., Fernandez X., Zurcher J., Kung T., Jones H., Watnick A.S., Gean R.W., Kreutner W., Adams G.K. Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. Am. Rev. Respir. Dis. 1993, 148:1623-1627.
102. McCafferty J., Griffiths A.D., Winter G., Chiswell D.J. Phage antibodies:filamentous phage displaying antibody variable domains. Nature 1990, 348:552-554.
103. Melnyk O., Zimmerman M., Kim K.J., Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J. Urol. 1999, 161:960-963.
104. Michalak-Stoma A., Pietrzak A., Szepietowski J.M., Zalewska-Janowska A., Paszkowski T., Chodorowska G. Cytokine network in psoriasis revisited. Eur. Cytokine Netw. 2012, 22:160-168.
105. Minamoto S., Itoh S., Kono T., Doi T., Hatakeyama M. Ligand-dependent selection of the receptor gene: Segregation of IL-2 binding activity and anti-Tac reactivity by a single amino acid alteration in the Tac antigen (p55). Immunol. Lett. 1989, 20:139-147.
106. Mizuma H., Litwin S., Zolla-Pazner S. B-cell activation in HIV infection: Relationship of spontaneous immunoglobulin secretion to various immunological parameters. Clin. Exp. Immunol. 1988, 71:410-416.
107. Möller G. Lipopolysaccharide as a tool to reveal autoreactive B cells. APMIS 1988, 96:93-100.
108. Morrison S.L., Johnson M.J., Herzenberg L.A., Oi V.T. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 1984, 81:6851-6855.
109. Neurath M.F., Fuss I., Kelsall B.L., Stüber E., Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 1995, 182:1281-1290.
110. Nguyen T.H., Casale T.B. Immune modulation for treatment of allergic disease. Immunol. Rev. 2011, 242:258-271.
111. Nicoletti F., Zaccone P., Di Marco R., Lunetta M., Magro G., Grasso S., Meroni P., Garotta G. Prevention of spontaneous autoimmune diabetes in diabetes-prone BB rats by prophylactic treatment with antirat interferon-gamma antibody. Endocrinology 1997, 13:281-288.
112. Obiri N.I., Siegel J.P., Varricchio F., Puri R.K. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin. Exp. Immunol. 1994, 95:148-155.
113. O'Garra A., Vieira P.L., Vieira P., Goldfeld A.E. IL-10-producing and naturallyoccurring CD4+ Tregs: Limiting collateral damage. J. Clin. Invest. 2004, 114:1372-1378.
114. Owyang A.M., Maedler K., Gross L., Yin J., Esposito L., Shu L., Jadhav J., Domsgen E., Bergemann J., Lee S., Kantak S. XOMA 052, an anti-IL-1 beta monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model. Endocrinology 2010, 151:2515-2527.
115. Owyang A.M., Issafras H., Corbin J., Ahluwalia K., Larsen P., Pongo E., Handa M., Horwitz A.H., Roell M.K., Haak-Frendscho M., Masat L. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases. MAbs 2011, 3:49-60.
116. Perper S.J., Browning B., Burkly L.C., Weng S., Gao C., Giza K., Su L., Tarilonte L., Crowell T., Rajman L., Runkel L., Scott M., et al. TWEAK is a novel arthritogenic mediator. J. Immunol. 2006, 177:2610-2620.
117. History of Vaccine Development 2011, Springer, NewYork, NY, Inc. S.A. Plotkin (Ed.).
118. Piguet P.F., Grau G.E., Vesin C., Loetscher H., Gentz R., Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992, 77:510-514.
119. Rad F.H., Le Buanec H., Paturance S., Larcier P., Genne P., Ryffel B., Bensussan A., Bizzini B., Gallo R.C., Zagury D., Uzan G. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc. Natl. Acad. Sci. USA 2007, 104:2837-2842.
120. Ratsimandresy R.A., Rappaport J., Zagury J.F. Anti-cytokine therapeutics: History and update. Curr. Pharm. Des. 2009, 15(17):1998-2025.
121. Ratsimandresy R.A., Duvallet E., Assier E., Semerano L., Delavallée L., Bessis N., Zagury J.F., Boissier M.C. Active immunisation against IL-23p19 improves experimental arthritis. Vaccine 2011, 29:9329-9336.
122. ® (infliximab) human prescription Drug Label 1998, Janssen Biotech, Inc, USA.
123. Richard M., Grencis R.K., Humphreys N.E., Renauld J.C., Van Snick J. Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc. Natl. Acad. Sci. USA 2000, 97:767-772.
124. Rodriguez P.C., Neninger E., García B., Popa X., Viada C., Luaces P., González G., Lage A., Montero E., Crombet T. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients. J. Immune Based Ther. Vaccines 2011, 9:7.
125. Röhn T.A., Jennings G.T., Hernandez M., Grest P., Beck M., Zou Y., Kopf M., Bachmann M.F. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur. J. Immunol. 2006, 36:2857-2867.
126. Rönnblom L., Alm G.V. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol. 2001, 22:427-431.
127. Rönnblom L., Elkon K.B. Cytokines as therapeutic targets in SLE. Nat. Rev. Rheumatol. 2010, 6:339-347. Review.
128. Ross C., Hansen M.B., Schyberg T., Berg K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin. Exp. Immunol. 1990, 82:57-62.
129. Sakaguchi S., Sakaguchi N., Shimizu J., Yamazaki S., Sakihama T., Itoh M., Kuniyasu Y., Nomura T., Toda M., Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 2001, 182:18-32.
130. Santin A.D., Hiserodt J.C., DiSaia P.J., Pećorelli S., Granger G.A. Differential effects of high-dose gamma irradiation on the production of transforming growth factor-beta in fresh and established human ovarian cancer. Gynecol. Oncol. 1996, 61:403-408.
131. Santin A.D., Hermonat P.L., Hiserodt J.C., Fruehauf J., Schranz V., Barclay D., Pecorelli S., Parham G.P. Differential transforming growth factor-beta secretion in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol. Oncol. 1997, 64:477-480.
132. Sato T., Terai M., Tamura Y., Alexeev V., Mastrangelo M.J., Selvan S.R. Interleukin10 in the tumor microenvironment: A target for anticancer immunotherapy. Immunol. Res. 2011, 51:170-182.
133. Selmaj K., Raine C.S., Cross A.H. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 1991, 30:694-700.
134. Sharma K., Jin Y., Guo J., Ziyadeh F.N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996, 45:522-530.
135. Shirahata S., Katakura Y., Teruya K. Cell hybridization, hybridomas, and human hybridomas. Methods Cell Biol. 1998, 57:111-145.
136. Siegel S.A., Shealy D.J., Nakada M.T., Le J., Woulfe D.S., Probert L., Kollias G., Ghrayeb J., Vilcek J., Daddona P.E. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995, 7:15-25.
137. Smitten A.L., Simon T.A., Hochberg M.C., Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res. Ther. 2008, 10:R45.
138. Sonderegger I., Rohn T.A., Kurrer M.O., Iezzi G., Zou Y., Kastelein R.A., Bachmann M.F., Kopf M. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur. J. Immunol. 2006, 36:2849-2856.
139. Spencer J.V., Lockridge K.M., Barry P.A., Lin G., Tsang M., Penfold M.E., Schall T.J. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J. Virol. 2002, 76:1285-1292.
140. Spohn G., Guler R., Johansen P., Keller I., Jacobs M., Beck M., Rohner F., Bauer M., Dietmeier K., Kündig T.M., Jennings G.T., Brombacher F., et al. A virus-like particle-based vaccine selectively targeting soluble TNF-α protects from arthritis without inducing reactivation of latent tuberculosis. J. Immunol. 2007, 178:7450-7457.
141. Spohn G., Keller I., Beck M., Grest P., Jennings G.T., Bachmann M.F. Active immunisation with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur. J. Immunol. 2008, 38:877-887.
142. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., Pardoll D., Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 1998, 95:1178-1183.
143. Stewart T.A., Hultgren B., Huang X., Pitts-Meek S., Hully J., MacLachlan N.J. Induction of type I diabetes by interferon-alpha in transgenic mice. Science 1993, 260:1942-1946.
144. Sunderkötter C., Steinbrink K., Goebeler M., Bhardwaj R., Sorg C. Macrophages and angiogenesis. J. Leukoc. Biol. 1994, 55:410-422.
145. Svenson M., Hansen M.B., Ross C., Diamant M., Rieneck K., Nielsen H., Bendtzen K. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 1998, 91:2054-2061.
146. Tan G.H., Wang C.C., Huang F.Y., Wang H., Huang Y.H., Lin Y.Y. Active immunotherapy of allergic asthma with a recombinant human interleukin-5 protein as vaccine in a murine model. Chin. Med. J. 2007, 120:1517-1522.
147. Tang H., Mignon-Godefroy K., Meroni P.L., Garotta G., Charreire J., Nicoletti F. The effects of a monoclonal antibody to interferon-gamma on experimental autoimmune thyroiditis (EAT): Prevention of disease and decrease of EAT-specific T cells. Eur. J. Immunol. 1993, 23:275-278.
148. Teicher B.A., Kakeji Y., Ara G., Herbst R.S., Northey D. Prostate carcinoma response to cytotoxic therapy: In vivo resistance. In Vivo 1997, 11:453-461.
149. Theofilopoulos A.N. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol. Today 1995, 16:90-98.
150. Thiernesse N., Jeannesson P., Bernard J., Zagury D., Voisin G.A. Classical and alloimmune anaphylactic degranulation of isolated single mast cells. J. Immunol. Methods 1978, 21:79-88.
151. Thomas E., Brewster D.H., Black R.J., Macfarlane G.J. Risk of malignancy among patients with rheumatic conditions. Int. J. Cancer 2000, 88:497-502.
152. Tripathi R.C., Borisuth N.S., Kolli S.P., Tripathi B.J. Trabecular cells express receptors that bind TGF-beta 1 and TGF-beta 2: A qualitative and quantitative characterization. Invest. Ophthalmol. Vis. Sci. 1993, 34:260-263.
153. Uyttenhove C., Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur. J. Immunol. 2006, 36:2868-2874.
154. Uyttenhove C., Arendse B., Stroobant V., Brombacher F., Van Snick J. Development of an anti-IL-12 p40 auto-vaccine: Protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur. J. Immunol. 2004, 34:3572-3581.
155. Uyttenhove C., Marillier R.G., Tacchini-Cottier F., Charmoy M., Caspi R.R., Damsker J.M., Goriely S., Su D., Van Damme J., Struyf S., Opdenakker G., Van Snick J. Amine-reactive OVA multimers for auto-vaccination against cytokines and other mediators: Perspectives illustrated for GCP-2 in L. major infection. J. Leukoc. Biol. 2011, 89:1001-1007.
156. Vaisman N., Gospodarowicz D., Neufeld G. Characterization of the receptors for vascular endothelial growth factor. J. Biol. Chem. 1990, 265:19461-19466.
157. Vaklavas C., Lenihan D., Kurzrock R., Tsimberidou A.M. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: What are the important clinical markers to target?. Oncologist 2010, 15:130-141.
158. van der Laken C.J., Voskuyl A.E., Roos J.C., Stigter van Walsum M., de Groot E.R., Wolbink G., Dijkmans B.A., Aarden L.A. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66:253-256.
159. Van Oosterhout A.J., Ladenius A.R., Savelkoul H.F., Van Ark I., Delsman K.C., Nijkamp F.P. Effect of anti-IL-5 and IL-5 on airway hyperreactivity and eosinophils in guinea pigs. Am. Rev. Respir. Dis. 1993, 147:548-552.
160. Vandepapeliere P., Malan F., Rogler G., van der Bijl A., Kruger F.C., Kruger D., Grouard-Vogel G., Dhellin O., Fanget B., Michetti P. Phase I-II safety, immunogenicity and clinical results of TNFa-kinoid immunotherapeutic immunization in Crohn's disease patients 2011, The 6th Congress ECCO 2011- the European Crohn's and Colitis Organization- Dublin, Ireland.
161. Vink A., Coulie P., Warnier G., Renauld J.-C., Stevens M., Donckers D., VanSnick J. Mouse plasmacytoma growth in vivo: Enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against interleukin 6 or its receptor. J. Exp. Med. 1990, 172:997.
162. Viscidi R.P., Mayur K., Lederman H.M., Frankel A.D. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 1989, 246:1606-1608.
163. Waterston A.M., Salway F., Andreakos E., Butler D.M., Feldmann M., Coombes R.C. TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br. J. Cancer 2004, 90:1279-1284.
164. Waterston A.M., Gumbrell L., Bratt T., Waller S., Gustav-Aspland J., L'hermenier C., Bellenger K., Campbell M., Powles T., Highley M., Bower M., Mouritsen S., et al. Phase I study of TNFalpha Auto VaccIne in patients with metastatic cancer. Cancer Immunol. Immunother. 2005, 54:848-857.
165. Watkins P.E., Warren B.F., Stephens S., Ward P., Foulkes R. Treatment of ulcerative colitis in the cotton top tamarin using antibody to tumour necrosis factor alpha. Gut 1997, 40:628-633.
166. Weiner G.J. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J. Leukoc. Biol. 2000, 68:455-463.
167. Williams R.O., Feldmann M., Maini R.N. Anti-TNF ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 1992, 89:9784-9788.
168. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy. J. Immunother. 1997, 20:165-177.
169. Xue X., Feng G., Li M., Qin X., Wu S., Zhang C., You Y., Wang W., Jiang C., Liu Y., Zhu W., Ran Y., et al. Amelioration of experimental autoimmune encephalomyelitis by BLyS autovaccine. Vaccine 2008, 26:2873-2881.
170. Yago T., Nanke Y., Kawamoto M., Furuya T., Kobashigawa T., Kamatani N., Kotake S. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res. Ther. 2007, 9:R96.
171. Zagury D. Anti-HIV cellular immunotherapy in AIDS. Lancet 1991, 338:694-695.
172. Zagury D., Lachgar A., Chams V., Fall L.S., Bernard J., Zagury J.F., Bizzini B., Gringeri A., Santagostino E., Rappaport J., Feldman M., Burny A., et al. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc. Natl. Acad. Sci. USA 1998, 95:3851-3856.
173. Zagury D., Burny A., Gallo R.C. Toward a new generation of vaccines: The anti-cytokine therapeutic vaccines. Proc. Natl. Acad. Sci. USA 2001, 98:8024-8029.
174. Zagury D., Le Buanec H., Bizzini B., Burny A., Lewis G., Gallo R.C. Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev. 2003, 14:123-137. Review.
175. Zagury D., Le Buanec H., Mathian A., Larcier P., Burnett R., Amoura Z., Emilie D., Peltre G., Bensussan A., Bizzini B., Gallo R.C., Koutouzov S. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc. Natl. Acad. Sci. USA 2009, 106:5294-5299.
176. Zauli G., Davis B.R., Re M.C., Visani G., Furlini G., La Placa M. tat protein stimulates production of transforming growth factor-beta 1 by marrow macrophages: A potential mechanism for human immunodeficiency virus-1-induced hematopoietic suppression. Blood 1992, 80:3036-3043.
177. Zauli G., Gibellini D., Celeghini C., Mischiati C., Bassini A., La Placa M., Capitani S. Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes. J. Immunol. 1996, 157:2216-2224.
178. Zeghidi H. Oral presentation at the annual EVER (European Association for Vision and Eye Research) Congress: "Anti-Angiogenic Effect of VEGF-Kinoid Immunotherapy on mice with experimental choroidal neovascularization" 2009.
179. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263-274.
180. Zou Y., Sonderegger I., Lipowsky G., Jennings G.T., Schmitz N., Landi M., Kopf M., Bachmann M.F. Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice. Vaccine 2010, 28:3192-3200.
181. Zuany-Amorim C., Manlius C., Dalum I., Jensen M.R., Gautam A., Pay G., Mouritsen S., Walker C. Induction of TNF-α autoantibody production by Auto Vac TNF106, a novel therapeutic approach for the treatment of allergic diseases. Int. Arch. Allergy Immunol. 2004, 133:154-163.